Physician profile
Farhad Hasan
NPI 1396995437
$3,263.43
in general payments reported to CMS, 2019-2025
10 companies · $76.67 in 2025
The $76.67 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.85 · 2020: $38.36 · 2021: $111 · 2022: $2,577 · 2023: $177 · 2024: $241 · 2025: $76.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $365 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.80 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,951.72 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $67.39 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Tandem Diabetes Care, INC. | $56.89 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $45.86 | 2023-2024 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $36.84 | 2022-2024 | Gvoke Hypopen |
| Beta Bionics, INC. | $24.97 | 2023 | Ilet Bionic Pancreas |
| Insulet Corporation | $24.07 | 2023 | Omnipod |
| Amgen INC. | $22.56 | 2025 | Evenity, Prolia |
| Abbott Laboratories | $18.91 | 2020 | |
| Recordati_rare_diseases_inc. | $14.22 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.